MedTrace Logo

Belgian Antithrombin Deficiency Registry

NCT05891899 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2024-12-04

No results posted yet for this study

Summary

Inherited antithrombin deficiency is a rare autosomal dominant disorder that predisposes to the development of venous thromboembolism, even at young age.

Inherited AT deficiency is considered the most severe form of inherited thrombophilia, increasing up to 40 times the risk of venous thrombosis.

Our center has been performing research on antithrombin deficiency for several years. Therefore, it was decided to initiate a registry for patients with inherited antithrombin deficiency with the goal to gain more insight into what drives the development of a thrombotic event in patients with AT deficiency, both at the environmental level (lifestyle, management of risk situations, presence of additional thrombotic risk factors…) and at the genetic level.

Conditions

  • Antithrombin III Deficiency

Interventions

OTHER

observation

No interventions planned: treatment of patients at the discretion of the treating/responsible physician

Sponsors & Collaborators

  • Universitair Ziekenhuis Brussel

    lead OTHER

Principal Investigators

  • Christelle Orlando, PhD · Universitair Ziekenhuis Brussel

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-31
Primary Completion
2030-12-31
Completion
2060-12-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05891899 on ClinicalTrials.gov